We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
+4.78%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$484M
AUM Growth
+$55.1M
Cap. Flow
+$73.1M
Cap. Flow %
15.11%
Top 10 Hldgs %
57.22%
Holding
53
New
11
Increased
11
Reduced
16
Closed
15

Top Buys

Rank Stock Value
1
PRCT icon
Procept Biorobotics
PRCT
+$43.2M
2
JANX icon
Janux Therapeutics
JANX
+$35.9M
3
NKTR icon
Nektar Therapeutics
NKTR
+$31M
4
VEEV icon
Veeva Systems
VEEV
+$23.9M
5
PHR icon
Phreesia
PHR
+$20.2M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$21.8M
2
BBIO icon
BridgeBio Pharma
BBIO
+$15.4M
3
ROIV icon
Roivant Sciences
ROIV
+$14M
4
DXCM icon
DexCom
DXCM
+$13.1M
5
IMVT icon
Immunovant
IMVT
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.58%
2 Industrials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TECX
26
Tectonic Therapeutic
TECX
$696M
$4.9M 1.01%
235,000
-144,254
-38% -$2.68M
CDNA icon
27
CareDx
CDNA
$2.58B
$4.71M 0.97%
250,000
-254,030
-50% -$4.26M
TERN
28
DELISTED
Terns Pharmaceuticals
TERN
$3.84M 0.79%
+95,000
New +$2.2M
RCKT icon
29
Rocket Pharmaceuticals
RCKT
$424M
$2.61M 0.54%
743,942
-524,023
-41% -$1.79M
KIDS icon
30
OrthoPediatrics
KIDS
$617M
$2.43M 0.5%
136,741
-171,966
-56% -$3.01M
OKUR
31
OnKure Therapeutics
OKUR
$153M
$2.37M 0.49%
816,909
+548,950
+205% +$1.64M
BBIO icon
32
BridgeBio Pharma
BBIO
$15B
$2.29M 0.47%
30,000
-234,500
-89% -$15.4M
ABVX
33
Abivax
ABVX
$9.89B
$2.29M 0.47%
+17,000
New +$1.85M
ACET icon
34
Adicet Bio
ACET
$84.8M
$2.11M 0.44%
+250,244
New +$2.77M
TEM
35
Tempus AI
TEM
$11.6B
$2.07M 0.43%
+35,000
New +$2.74M
TBI
36
Trueblue
TBI
$326M
$2.01M 0.42%
442,554
+363,078
+457% +$1.86M
PLRX icon
37
Pliant Therapeutics
PLRX
$68.7M
$1.9M 0.39%
1,555,744
+1,535,257
+7,494% +$2.31M
RNTX
38
Rein Therapeutics
RNTX
$65.7M
$513K 0.11%
442,600
-125,298
-22% -$173K
ACHC icon
39
Acadia Healthcare
ACHC
$2.66B
– –
-250,000
Closed -$6.19M
AKRO
40
DELISTED
Akero Therapeutics
AKRO
– –
-39,072
Closed -$1.86M
ALGN icon
41
Align Technology
ALGN
$11.2B
– –
-19,442
Closed -$2.43M
ARGX icon
42
argenx
ARGX
$64B
– –
-3,300
Closed -$2.43M
BHVN icon
43
Biohaven
BHVN
$2.33B
– –
-600,000
Closed -$9.01M
CORT icon
44
CALL
Corcept Therapeutics
CORT
$12.3B
– –
-147,800
Closed -$12.3M
CTMX icon
45
CytomX Therapeutics
CTMX
$699M
– –
-564,800
Closed -$1.8M
DXCM icon
46
DexCom
DXCM
$34.3B
– –
-195,217
Closed -$13.1M
ISRG icon
47
Intuitive Surgical
ISRG
$132B
– –
-48,711
Closed -$21.8M
PRTA icon
48
Prothena Corp
PRTA
$479M
– –
-20,000
Closed -$195K
SDGR icon
49
Schrodinger
SDGR
$1.47B
– –
-34,830
Closed -$699K
SGHT icon
50
Sight Sciences
SGHT
$471M
– –
-439,941
Closed -$1.51M
1
2
3

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q4 2025 Portfolio in Review

As of Q4 2025, Prosight Management held 53 positions worth $484M, up 13% from $429M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Prosight Management deployed $73.1M of net new capital in Q4 2025, opening 11 new positions and adding to 11 existing holdings. Its largest new stake was Nektar Therapeutics: 554,633 shares worth $23.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was BridgeBio Pharma, an estimated $15.4M trimmed.

  • Prosight Management's largest Q4 2025 buy was Nektar Therapeutics: 554,633 shares worth $23.4M.
  • Prosight Management added most to Procept Biorobotics in Q4 2025, an estimated $43.2M increase.
  • Prosight Management's biggest Q4 2025 reduction was BridgeBio Pharma, cutting an estimated $15.4M.
  • Prosight Management fully exited Intuitive Surgical in Q4 2025, selling an estimated $21.8M.
  • Prosight Management's ten largest holdings make up 57% of its $484M portfolio in Q4 2025.
  • Prosight Management opened 11 new positions and closed 15 in Q4 2025.
  • Prosight Management's portfolio value rose 13% quarter-over-quarter to $484M.

Based on Prosight Management's 13F filing for Q4 2025, filed 13 Feb 2026.